# The Potential Role of Ga-68-PSMA in Staging, Restaging and Monitoring Response in Primary Liver Cancer: Comparison With F-18-FDG

> **NCT03138239** · NA · UNKNOWN · sponsor: **Tel-Aviv Sourasky Medical Center** · enrollment: 16 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **RADIATION:** Ga-68-PSMA scan, and PET -CT F-18-FDG

## Key facts

- **NCT ID:** NCT03138239
- **Lead sponsor:** Tel-Aviv Sourasky Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-07-02
- **Primary completion:** 2018-07-02
- **Final completion:** 2019-07-02
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2017-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03138239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03138239, "The Potential Role of Ga-68-PSMA in Staging, Restaging and Monitoring Response in Primary Liver Cancer: Comparison With F-18-FDG". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03138239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*